![1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea structure](/static/products/827/827003-47-4.png)
1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea
TL;DR: 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea (CAS 827003-47-4) is a chemical compound with molecular formula C25H31N5O and molecular weight 417.25 g/mol, supplied by Kehong Biological (Henan Kehong Biological Technology Co., Ltd.) with CRO/CDMO custom synthesis services.
1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea
Also Known As: 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea, 1-cyclohexyl-3-[2-(1-phenylethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]urea, N-CYCLOHEXYL-N'-[2-(1-PHENYLETHYL)-1,2,3,4-TETRAHYDROPYRAZINO[1,2-A][1,3]BENZIMIDAZOL-8-YL]UREA, N-cyclohexyl-N'-[2-(1-phenylethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]benzimidazol-8-yl]urea
| Molecular Formula | C25H31N5O |
|---|---|
| Molecular Weight | 417.25 g/mol |
| LogP | 5.0673 |
| Topological Polar Surface Area | 62.19 Ų |
| Hydrogen Bond Donors | 2 |
| Hydrogen Bond Acceptors | 3 |
| Rotatable Bonds | 4 |
| Exact Mass | 417.25287 |
| Heavy Atoms | 31 |
| Complexity | 1054.4645 |
Chemical Identifiers
| CAS Number | 827003-47-4 |
|---|---|
| SMILES | CC(C1=CC=CC=C1)N2CCN3C(=NC4=C3C=CC(=C4)NC(=O)NC5CCCCC5)C2 |
Product Overview
1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea (CAS 827003-47-4), with molecular formula C25H31N5O and molecular weight 417.25 g/mol. IUPAC: 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea.
Chemical Property Profile of 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea
Property Insights of 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea
The XLogP value of 5.0673 indicates that 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea is lipophilic (fat-soluble), which may influence its absorption, distribution, and formulation strategy. The TPSA of 62.19 Ų falls within the moderate polarity range, balancing permeability and solubility for 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea. Following Lipinski's Rule of Five, 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea has 2 hydrogen bond donor(s) and 3 hydrogen bond acceptor(s), which may warrant consideration for formulation optimization.
Frequently Asked Questions
Frequently Asked Questions
What is the CAS number of 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea?
The CAS number of 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea is 827003-47-4.
What is the molecular formula of 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea?
The molecular formula of 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea is C25H31N5O.
What is the molecular weight of 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea?
The molecular weight of 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea is 417.25 g/mol.
Where can I buy 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea?
You can request a quote for 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea directly from KEHONG BIO. Contact us or email info@kehongbio.com for pricing and availability.
Does KEHONG BIO offer custom synthesis for 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea?
Yes, KEHONG BIO provides custom synthesis services for 1-cyclohexyl-3-[2-(1-phenylethyl)-3,4-dihydro-1H-pyrazino[1,2-a]benzimidazol-8-yl]urea and related compounds. Contact us with your specific requirements including quantity, purity, and timeline.